Clinical impact of the pathological quantification of myocardial fibrosis and infiltrating T lymphocytes using an endomyocardial biopsy in patients with hypertrophic cardiomyopathy
- PMID: 35662562
- DOI: 10.1016/j.ijcard.2022.05.068
Clinical impact of the pathological quantification of myocardial fibrosis and infiltrating T lymphocytes using an endomyocardial biopsy in patients with hypertrophic cardiomyopathy
Abstract
Background: The impact of quantitative pathological findings derived from endomyocardial biopsies (EMB) on clinical prognosis in patients with hypertrophic cardiomyopathy (HCM) remains unclear.
Methods: We retrospectively studied 55 consecutive HCM patients who underwent EMB. We quantified the collagen area fraction (CAF), the cardiomyocyte diameter, the nuclear area and circularity, and the number of myocardial infiltrating CD3+ cells using EMB samples by image analyzing software. The primary clinical endpoint was defined as a composite including cardiovascular death, admission due to heart failure and ventricular arrhythmia.
Results: During the median follow-up of 37.2 months, the primary endpoint was found in 12 patients. No significant difference in the risk score of 5-year sudden cardiac death was observed between the event-occurrence group and the event-free group. In the multivariable Cox proportional-hazard analysis, CAF [hazard ratio (HR) per 10% increase: 1.555, 95% CI: 1.014-2.367, p = 0.044] and the number of infiltrating CD3+ cells (HR per 10% increase: 1.231, 95% CI: 1.011-1.453, p = 0.041) were the independent predictors of the primary endpoint, while the myocardial diameter and the nuclear irregularity had no significant prognostic impact. Kaplan-Meier survival curves demonstrated that patients with both higher CAF and higher number of CD3+ cells had the worst prognosis (log-rank, P < 0.001).
Conclusions: The higher CAF and the higher number of infiltrating CD3+ cells quantified using EMB samples were the independent predictors of poor clinical outcomes in patients with HCM. Cardiomyocyte diameter and nuclear irregularity did not significantly impact the clinical prognosis.
Keywords: Endomyocardial biopsy; Hypertrophic cardiomyopathy; Inflammatory cell; Myocardial diameter; Myocardial fibrosis; Nuclear irregularity.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Clinical impact of combined assessment of myocardial inflammation and fibrosis using myocardial biopsy in patients with dilated cardiomyopathy: a multicentre, retrospective cohort study.Open Heart. 2025 Mar 12;12(1):e003250. doi: 10.1136/openhrt-2025-003250. Open Heart. 2025. PMID: 40081931 Free PMC article.
-
Myocardial T-Lymphocytes as a Prognostic Risk-Stratifying Marker of Dilated Cardiomyopathy - Results of the Multicenter Registry to Investigate Inflammatory Cell Infiltration in Dilated Cardiomyopathy in Tissues of Endomyocardial Biopsy (INDICATE Study).Circ J. 2022 Jun 24;86(7):1092-1101. doi: 10.1253/circj.CJ-21-0529. Epub 2022 Mar 10. Circ J. 2022. PMID: 35264513
-
Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.Heart Vessels. 2016 Mar;31(3):416-26. doi: 10.1007/s00380-014-0618-0. Epub 2014 Dec 25. Heart Vessels. 2016. PMID: 25539624
-
MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.Curr Med Chem. 2021;28(36):7400-7412. doi: 10.2174/0929867328666210405122703. Curr Med Chem. 2021. PMID: 33820510 Review.
-
Long-Term Prognosis of Suspected Myocarditis and Cardiomyopathy Associated with Viral Infection of the Myocardial Tissue: A Meta-Analysis of Cohort Studies.Cardiovasc Ther. 2019 Dec 16;2019:9342792. doi: 10.1155/2019/9342792. eCollection 2019. Cardiovasc Ther. 2019. PMID: 31921354 Free PMC article.
Cited by
-
Phenotype-Based Classification of Obstructive Hypertrophic Cardiomyopathy Undergoing Myectomy.JACC Basic Transl Sci. 2025 May;10(5):568-583. doi: 10.1016/j.jacbts.2024.12.016. Epub 2025 Mar 26. JACC Basic Transl Sci. 2025. PMID: 40183732 Free PMC article.
-
Clinical impact of combined assessment of myocardial inflammation and fibrosis using myocardial biopsy in patients with dilated cardiomyopathy: a multicentre, retrospective cohort study.Open Heart. 2025 Mar 12;12(1):e003250. doi: 10.1136/openhrt-2025-003250. Open Heart. 2025. PMID: 40081931 Free PMC article.
-
Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy.BMC Cardiovasc Disord. 2024 Apr 9;24(1):203. doi: 10.1186/s12872-024-03859-2. BMC Cardiovasc Disord. 2024. PMID: 38594610 Free PMC article.
-
Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.ESC Heart Fail. 2025 Feb;12(1):582-591. doi: 10.1002/ehf2.15109. Epub 2024 Oct 17. ESC Heart Fail. 2025. PMID: 39417989 Free PMC article.
-
Necroptosis and immune infiltration in hypertrophic cardiomyopathy: novel insights from bioinformatics analyses.Front Cardiovasc Med. 2024 Jun 14;11:1293786. doi: 10.3389/fcvm.2024.1293786. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38947229 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical